CD30 is a member of the tumor necrosis factor family of cell surface receptors normally expressed in lymphocytes, as well as some lymphomas, but has been described in other malignancies. Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor that belongs to the insulin receptor superfamily, and is normally expressed in neural cells, but has been detected in several malignancies. There is conflicting data in the literature that describes the expression of these receptors in breast cancer, and the aim of this study is to test the expression of CD30 and ALK in a cohort of Middle Eastern patients with breast carcinoma.Cases of invasive breast cancer from the archives of AUBMC were reviewed over a period of 9 years, and the blocks that were used for immunohistochemical staining for ER, PR, Her-2/neu were selected. Immunohistochemical staining for CD30 (JCM182) and ALK (5A4 and D5F3) was performed.Two hundred eighty-four cases were identified (2 cases were male), with a mean age of 55 ± 12. CD30 and ALK expression was not seen in any of the cases.Our cohort showed complete negativity to both CD30 and ALK, adding to the conflicting data available in the literature, and more studies are needed to reliably identify a trend of expression of CD30 and ALK in breast carcinoma, especially in the Middle East.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709128 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000016702 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancement to effusion: Breast implant-associated anaplastic large cell lymphoma.
J Cardiol Cases
December 2024
Department of Internal Medicine, University of Texas at Austin Dell Medical School, Austin, TX, USA.
Unlabelled: This case is a rare presentation of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), where malignant pericardial effusion (MPE) served as the primary manifestation. A 58-year-old woman, post-breast implant removal, presented with pleuritic chest pain, fever, and chills. Clinical evaluation revealed jugular venous distention, muffled heart sounds, and hemodynamic instability.
View Article and Find Full Text PDFPrimary cutaneous rhabdomyosarcoma with EWSR1/FUS::TFCP2 fusion: four new cases with distinctive morphology, immunophenotypic, and genetic profile.
Virchows Arch
December 2024
Department of Pathology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
EWSR1/FUS::TFCP2-rearranged rhabdomyosarcoma (RMS) is a rare tumor with an aggressive clinical course, a predilection for craniofacial bones, spindled and/or epithelioid histomorphology, and positive immunohistochemistry (IHC) for epithelial and myogenic markers, along with variable ALK expression. Herein, we present four additional cases of primary cutaneous TFCP2-rearranged RMS. Notably, one tumor (case 1) displayed a varied pathological spectrum, initially presenting as a low-grade spindle cell neoplasm, but progressed into a high-grade spindle/epithelioid tumor.
View Article and Find Full Text PDFPrimary Cutaneous Anaplastic Large Cell Lymphoma With Rare Extracutaneous Disseminated Disease: A Case Report.
Am J Dermatopathol
December 2024
Department of Dermatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA; and.
Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a CD30+ lymphoproliferative disorder with generally favorable outcomes and infrequent extracutaneous spread, usually limited to local lymph nodes. However, there may be extensive histologic overlap with more aggressive CD30+ lymphomas, such as large cell transformation of mycosis fungoides or secondary skin involvement by anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma. Definitive diagnosis relies on clinicopathologic correlation.
View Article and Find Full Text PDFAnaplastic Large B-Cell Lymphoma: Cutaneous Presentations.
Cureus
October 2024
Department of Dermatology, Marshall University Joan C. Edwards School of Medicine, Huntington, USA.
Article Synopsis
- Anaplastic large cell lymphoma (ALCL) is a rare T-cell lymphoma marked by the presence of CD30 and can often be mistaken for other conditions due to its vague symptoms.
- A 10-year-old girl initially treated for a bacterial infection was later diagnosed with ALK-negative ALCL after a biopsy revealed the disease, with additional imaging showing lung involvement and a Murphy stage II classification.
- The case highlights the necessity of early biopsy and molecular testing when initial treatments don't work, emphasizing that prompt diagnosis and thorough examinations can significantly enhance treatment success and patient prognosis.
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma.
Br J Cancer
December 2024
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Background: Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive T-cell lymphoma, classified into ALK-positive and ALK-negative subtypes, based on the presence of chromosomal translocations involving the ALK gene. The current standard of treatment for ALCL is polychemotherapy, with a high overall survival rate. However, a subset of patients does not respond to or develops resistance to these therapies, posing a serious challenge for clinicians.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!